Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 12/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4600764 | 0.85 | BDKRB2 (0.61) | BDKRB2PTGDR2KDM4EPOLBMAPT | |
| SCHEMBL4600398 | 0.80 | BDKRB2 (0.58) | BDKRB2PTGDR2KDM4EPOLBMAPT | |
| SCHEMBL4600400 | 0.80 | BDKRB2 (0.58) | BDKRB2PTGDR2KDM4EPOLBMAPT | |
| SCHEMBL4602993 | 0.76 | BDKRB2 (0.54) | BDKRB2PTGDR2KDM4EPOLBMAPT | |
| SCHEMBL6646929 | 0.72 | GAA (0.52) | BDKRB2PTGDR2KDM4EPOLBMAPT | |
| SCHEMBL4616222 | 0.72 | BDKRB2 (1.00) | BDKRB2 | |
| SCHEMBL6643730 | 0.72 | BDKRB2 (0.56) | BDKRB2 | |
| SCHEMBL7011457 | 0.72 | BDKRB2 (0.54) | BDKRB2PTGDR2KDM4ELMNAMEN1 | |
| SCHEMBL6646927 | 0.70 | BDKRB2 (0.48) | BDKRB2PTGDR2 | |
| SCHEMBL4600928 | 0.69 | MEN1 (0.61) | BDKRB2PTGDR2KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914236-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | Ortho-McNeil Pharmaceutical, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| US-7358261-B2 | Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-6958349-B2 | Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20050159443-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | CARSON JOHN R (US) | 2005-07-21 | — | — | US | disclosed |
| EP-1495017-A2 | NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040192720-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2003087090-A2 | NOVEL HETEROARYL ALKYLAMIDE DERIVATIVES USEFUL AS BRADYKININ RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL,INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192720-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | BDKRB2, BDKRB1, MRGPRX1 | BDKRB2 1/4885PTGDR2 65/4885KDM4E 1624/4885 |
| US-20050159443-A1 | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | BDKRB2, BDKRB1, MRGPRX1 | BDKRB2 1/4885PTGDR2 65/4885KDM4E 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.